睾酮治疗对伴有2型糖尿病和功能性性腺功能减退的肥胖男性骨转换标志物的影响。

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2022-12-01 DOI:10.1080/13685538.2022.2134338

Kristina Groti Antonič

{"title":"睾酮治疗对伴有2型糖尿病和功能性性腺功能减退的肥胖男性骨转换标志物的影响。","authors":"Kristina Groti Antonič","doi":"10.1080/13685538.2022.2134338","DOIUrl":null,"url":null,"abstract":"Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm2; p = 0.019) in group T following two years of treatment.Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":"25 1","pages":"269-277"},"PeriodicalIF":2.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.\",\"authors\":\"Kristina Groti Antonič\",\"doi\":\"10.1080/13685538.2022.2134338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm2; p = 0.019) in group T following two years of treatment.Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.\",\"PeriodicalId\":55542,\"journal\":{\"name\":\"Aging Male\",\"volume\":\"25 1\",\"pages\":\"269-277\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aging Male\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13685538.2022.2134338\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2022.2134338","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 3

摘要

方法:55名患有2型糖尿病和功能性性腺功能减退症的肥胖男性参与了一项为期2年的双盲、安慰剂对照研究。在基线、12和24个月时评估骨转换标志物I型胶原c端肽(CTX)和I型前胶原n端前肽(PINP)。24个月后采用双能x线骨密度仪评估骨密度变化。T组(n = 28)每年均接受TU治疗。P组(n = 27)第一年使用安慰剂，第二年使用TU。结果:P组CTX由1055(676-1344)降至453 (365-665)pmol/L (P P = 0.030)， T组为4.64±8.86 μg/L (P n = 16 /组)。腰椎骨密度增高(0.075±0.114 g/cm2;p = 0.019)。结论:经过两年的睾酮治疗，我们观察到CTX降低，PINP降低，腰椎骨密度增加。临床试验:NCT03792321;回顾性注册试验于2019年1月4日进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.

Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.

Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm²; p = 0.019) in group T following two years of treatment.

Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.

Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.